VEGFA and wet macular degeneration: Initial randomized phase III clinical trials, such as MARINA and ANCHOR, established monthly intravitreal anti-VEGF injections as the gold standard for the treatment of neovascular age-related macular degeneration [nAMD, 3, 4].